Allele-specific copy number analysis (ASCNA) is critical to define the extent of tumor suppressor loss of function (LOF) and contextualize the clinical response to synthetic lethal (SL) agents.
Targeting tumor suppressors through SL is poised to usher in a new wave of precision oncology, but there remains a need for assays that provide reliable ASCNA.
In this on-demand corporate workshop, you will learn more about how:
Director of Bioinformatics
Repare Therapeutics
Senior Commercial Product Manager
Integrated DNA Technologies